Evaluation of efficacy in improvement of cardiac function / renal function by REZALTAS COMBINATION TABLETS on hypertension patient.

Evaluation of efficacy in improvement of cardiac function / renal function by REZALTAS COMBINATION TABLETS on hypertension patient. - Evaluation of efficacy of REZALTAS COMBINATION TABLETS on hypertension patient.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005140

Enrollment

Registered

2011-03-01

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

olmesartan medoxomil 20mg REZALTAS COMBINATION TABLETS (olmesartan medoxomil 20mg, azelnidipine 16mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patient who can not control blood pressure by concomitant medication therapy on essential hypertension. (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg) 2)20 years old and more than it. 3)Informed consent.

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension 2)Known history of cerebral apoplexy. 3)Hyperkalemia (K>5.0mEq/L) 4)Serum Cr>3.0mg/dl 5)Severe hepatic disease. 6)Woman who are pregnant or woman of childbearing potential. 7)Patient who has olmesartan allergy or azelnidipine allergy.

Design outcomes

Primary

Measure	Time frame
Improvement of cardiac function. Improvement of renal function.	—

Secondary

Measure	Time frame
BNP MDA-LDL renin aldosterone norepinephrine home blood pressure in early morning home heart rate in early morning double product	—

Countries

Japan

Contacts

Public ContactYasuyuki Kawai

Kanazawa Medical University Hospital Department of Cardiology

kawai@kanazawa-med.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026